These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 6760961)
1. Immunotherapy for remission maintenance in acute myeloblastic leukemia. Baker MA; Taub RN; Carter WH Cancer Immunol Immunother; 1982; 13(2):85-8. PubMed ID: 6760961 [TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Whiteside MG; Cauchi MN; Paton C; Stone J Cancer; 1976 Oct; 38(4):1581-6. PubMed ID: 1068741 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of acute myelogenous leukemia in man. Powles R Natl Cancer Inst Monogr; 1973 Dec; 39():243-7. PubMed ID: 4595324 [No Abstract] [Full Text] [Related]
4. Active specific immunotherapy for acute myelogenous leukaemia. Powles R Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353 [No Abstract] [Full Text] [Related]
5. Perspectives and prospectives in the management of acute leukemia. Henderson ES Hamatol Bluttransfus; 1976; 19():305-10. PubMed ID: 795745 [No Abstract] [Full Text] [Related]
6. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions. Harris R; Zuhrie SR; Freeman CB; Taylor GM; MacIver JE; Geary CG; Delamore IW; Hull PJ; Tooth JA Br J Cancer; 1978 Feb; 37(2):282-8. PubMed ID: 272913 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and immunotherapy interspersion: clinical studies in acute myeloblastic leukaemia. Whittaker JA Recent Results Cancer Res; 1977; (62):90-4. PubMed ID: 341252 [No Abstract] [Full Text] [Related]
10. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte function in myeloblastic leukaemia. Wilkinson PM; Sumner C; Delamore IW; Geary CG; Milner GR Br J Cancer; 1975 Nov; 32(5):574-7. PubMed ID: 764849 [TBL] [Abstract][Full Text] [Related]
15. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279 [TBL] [Abstract][Full Text] [Related]
16. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse. Powles R; Toy JL Haematologia (Budap); 1976; 10(1):5-9. PubMed ID: 1070466 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and immunotherapy for acute myelogenous leukemia. Lister TA; Whitehouse JM; Oliver RT; Bell R; Johnson SA; Wrigley PF; Ford JM; Cullen MH; Gregory W; Paxton AM; Malpas JS Cancer; 1980 Nov; 46(10):2142-8. PubMed ID: 6932992 [TBL] [Abstract][Full Text] [Related]
18. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813 [TBL] [Abstract][Full Text] [Related]